Abstract Library

#2002 Pulmonary Function Test Physiology and Progression in Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare condition characterised by a generalised proliferation of pulmonary neuroendocrine cells within the respiratory epithelium. Little is known of its affects on pulmonary function both at the time of diagnosis and prospectively.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Barlow J

Authors: Barlow J, Ryan D, Mansoor W, Howell M, Clayton N,

Keywords: Neuroendocrine, Cell, Pulmonary, Function, Hyperplasia, Pulmonary function, Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, DIPNECH, Physiology,

#1574 Somatostatin Receptors Profile in Pulmonary NETs Associated with DIPNECH

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare entity characterised histologically by the proliferation of neuroendocrine cells along the distal bronchiolar epithelium, associated with small tumourlets and usually found in association with pulmonary carcinoid tumour. This can be clinically silent or may be associated with symptomatic obstructive bronchiolitis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Fabre A

Authors: Ryan C, Fabre A, Di Capua D, Swan N, Power D,

Keywords: SSTR, DIPNECH, carcinoid,

#403 Insulinomas in Children

Introduction: Insulinomas are extremely rare tumors in children and an uncommon first manifestation of MEN1 syndrome. Insulinomas are usually benign tumors with only a few reports of malignant cases in children.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Melikian M, Gurevich L, Averyanova Y, Friis-Hansen L, Christesen H,

Keywords: MEN-1,

#53 The rise and fall of chromogranin A as an indicator for NET

Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Armstrong L, Ryan K, Ardill J,

Keywords: Chromogranin A, proton pump inhibitors, gastrin, audit, case report,